Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.
Berger T, Shochat T, Aumann S, Nachmias B, Goldschmidt N, Horesh N, Harel R, Aviv A, Shmerts E, Abadi U, Shimony S, Raanani P, Gafter-Gvili A, Gurion R. Berger T, et al. Among authors: aumann s. Ann Hematol. 2023 Aug;102(8):2127-2136. doi: 10.1007/s00277-023-05306-2. Epub 2023 Jun 19. Ann Hematol. 2023. PMID: 37335322
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.
Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, Kahn JE, Trad S, Nizard P, Donadieu J, Taly V, Amoura Z, Abdel-Wahab O, Haroche J. Emile JF, et al. Among authors: aumann s. Blood. 2014 Nov 6;124(19):3016-9. doi: 10.1182/blood-2014-04-570937. Epub 2014 Aug 22. Blood. 2014. PMID: 25150293 Free PMC article.
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S, Ramirez-Labrada A, Aumann S, Lu X, Weich N, Santiago G, Cortizas EM, Sharabi E, Zhang Y, Sanchez-Garcia I, Gentles AJ, Roberts E, Bilbao-Cortes D, Vega F, Chapman JR, Verdun RE, Lossos IS. Parvin S, et al. Among authors: aumann s. Cancer Cell. 2019 Sep 16;36(3):237-249.e6. doi: 10.1016/j.ccell.2019.07.007. Epub 2019 Aug 22. Cancer Cell. 2019. PMID: 31447348 Free PMC article.
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.
Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, Li Y, Chung YR, Micol JB, Murphy ME, Cho H, Kim MK, Zebari AS, Aumann S, Park CY, Buonamici S, Smith PG, Deeg HJ, Lobry C, Aifantis I, Modis Y, Allain FH, Halene S, Bradley RK, Abdel-Wahab O. Kim E, et al. Among authors: aumann s. Cancer Cell. 2015 May 11;27(5):617-30. doi: 10.1016/j.ccell.2015.04.006. Cancer Cell. 2015. PMID: 25965569 Free PMC article.
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.
Levy I, Lavi A, Zimran E, Grisariu S, Aumann S, Itchaki G, Berger T, Raanani P, Harel R, Aviv A, Lavi N, Zuckerman T, Shvidel L, Jarchowsky O, Ellis M, Herzog Tzarfati K, Koren-Michowitz M, Sherf Y, Levi I, Sofer O, Shpilberg O, Dally N, Suriu C, Braester A, Ben Barouch S, Leiba M, Goldstein D, Sarid N, Yeganeh S, Halloun J, Mittelman M, Tadmor T. Levy I, et al. Among authors: aumann s. Leuk Lymphoma. 2021 Dec;62(14):3384-3393. doi: 10.1080/10428194.2021.1966782. Epub 2021 Aug 18. Leuk Lymphoma. 2021. PMID: 34405767
Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis.
Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I, Frisch A, Ganzel C, Vainstein V, Moshe Y, Aumann S, Yeshurun M, Ofran Y, Raanani P, Wolach O. Shimony S, et al. Among authors: aumann s. Ann Hematol. 2022 Sep;101(9):2011. doi: 10.1007/s00277-022-04929-1. Ann Hematol. 2022. PMID: 35869985 No abstract available.
31 results